0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Siglec-2

Siglec-2

Siglec-2 Molecule Information

Name:CD22
Target Synonym:SIGLEC2;B-lymphocyte cell adhesion molecule;Sialic acid-binding Ig-like lectin 2;Siglec-2;CD_antigen=CD22;T-cell surface antigen Leu-14;CD22;BL-CAM;B-cell receptor CD22
Number of Launched Drugs:2
Number of Drugs in Clinical Trials:33
Lastest Research Phase:Approved

Siglec-2 Protein Product ListCompare or Buy

Siglec-2 Part of Bioactivity data

SI2-HF2H6-Cell-based assay
Evaluation of CAR expression

293 cells were transfected with anti-CD22-scFv and RFP tag. 2e5 of the cells were stained with B. FITC-Labeled Human Siglec-2, His Tag (Cat. No. SI2-HF2H6, 10 µg/mL) and C. FITC-labeled Protein Control. A. Non-transfected 293 cells and C. FITC-labeled Protein Control were used as negative control. RFP was used to evaluate CAR (anti-CD22-scFv) expression and FITC was used to evaluate the binding activity of FITC-Labeled Human Siglec-2, His Tag (Cat. No. SI2-HF2H6) (QC tested).

SI2-H5228-SPR
Human_FcRn_Heterodimer_Protein_SPR

Anti-Human CD22 MAb (human IgG1) captured on CM5 chip via Anti-Human IgG Fc antibodies surface, can bind Human Siglec-2 (176-687), His Tag (Cat. No. SI2-H5228) with an affinity constant of 11.5 nM as determined in a SPR assay (Biacore T200) (Routinely tested).

CD2-H52H8-BLI
Human_FcRn_Heterodimer_Protein_Bli

Loaded Anti-Human CD22 MAb (human IgG1) on AHC Biosensor, can bind Human Siglec-2, His Tag (Cat. No. CD2-H52H8) with an affinity constant of 133 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

Siglec-2 Molecule Synonym Name

CD22,SIGLEC2,BL-CAM,Leu-14

Siglec-2 Molecule Background

B-cell receptor CD22 is also known as Sialic acid-binding Ig-like lectin 2 (Siglec-2), B-lymphocyte cell adhesion molecule (BL-CAM), T-cell surface antigen Leu-14, which belongs to the immunoglobulin superfamily and SIGLEC (sialic acid binding Ig-like lectin) family. CD22 mediates B-cell B-cell interactions, and may be involved in the localization of B-cells in lymphoid tissues. Siglec-2 / CD22 binds sialylated glycoproteins, one of which is CD45. Siglec2 / CD22 plays a role in positive regulation through interaction with Src family tyrosine kinases and may also act as an inhibitory receptor by recruiting cytoplasmic phosphatases via their SH2 domains that block signal transduction through dephosphorylation of signaling molecules.

Siglec-2 References

Siglec-2 Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Moxetumomab pasudotox CAT-8015; GCR-8015; HA-22 Approved AstraZeneca LUMOXITI fda ASTRAZENECA AB 2018-09-13 Hairy cell leukemia Details
Inotuzumab Ozogamicin CMC-544; PF-5208773; WAY-207294,CMC544,PF5208773,WAY207294 Approved Pfizer, UCB inotuzumab ozogamicin ema Pfizer Europe MA EEIG 2017-06-28 Acute lymphoblastic leukaemia (ALL) Details

Siglec-2 Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
CD22-CART Phase Ⅰ Shanghai Hrain Biotechnology Mantle cell lymphoma (MCL), Diffuse large B cell lymphoma, Follicular lymphoma Details
Anti-CD19 anti-CD22 bispecific chimeric antigen receptor T cell therapy (Hrain Biotechnology) Phase Ⅰ Hrain Biotechnology Lymphoblastic leukaemia Details
AUTO-3 AUTO-3,AUTO3 Phase Ⅱ University College London, Autolus B-cell lymphoma, Acute lymphoblastic leukaemia (ALL) Details
Anti-CD22 CAR-T cell therapy (No. 307 Hospital) Phase Ⅱ No 307 Hospital of the Chinese People’s Liberation Army Acute lymphoblastic leukaemia (ALL) Details
SM-03 SM-03; SM-06 Phase Ⅲ Lonn Ryonn Pharma, SinoMab Bioscience Ltd Rheumatoid arthritis (RA) Details
Anti-CD19/CD22 chimeric antigen receptor T cell therapy (Nanjing Legend Biotech) LCAR-L10D Phase Ⅰ Second Affiliated Hospital of Xi'an Jiaotong University, Nanjing Legend Biotech Diffuse large B cell lymphoma Details
JCAR-018 JCAR-018 Phase Ⅰ National Cancer Institute, Opus Bio, Juno Therapeutics Acute lymphoblastic leukaemia (ALL), Non-Hodgkin B-cell lymphomas Details
CD19 and CD22 targeted CAR-T cell therapy (Chongqing Xinqiao Hospital) Phase Ⅰ Chongqing Xinqiao Hospital B-cell lymphoma Details
CD20/CD22 dual Targeted CAR T-cell therapy (Zhejiang University) Phase Ⅰ Zhejiang University Lymphoid Hematological Malignancies Details
RD-102 RD-102 Phase Ⅰ Nanjing IASO Biotherapeutics Lymphoblastic leukaemia, Diffuse large B cell lymphoma Details
BAY-1862864 BAY-1862864 Phase Ⅰ Bayer Non-Hodgkin's lymphoma (NHL) Details
Epratuzumab AMG-412; CDP-3194; IMMU-103; IMMU-1903; IMMU-hLL2,AMG412,CDP3194,IMMU103,IMMU1903,IMMUhLL2 Phase Ⅲ Immunomedics, UCB Sjoegren's syndrome, Systemic lupus erythematosus, Acute lymphoblastic leukaemia (ALL) Details
GTB-1550 DT-2219ARL; DT-2219; IND-100780; OXS-1550 Phase Ⅱ University of Minnesota, Oxis International, GT Biopharma B-cell lymphoma, Leukemia Details
Autologous CD19/CD22 chimeric antigen receptor T-cell therapy (MD Anderson Cancer Center) Phase Ⅱ M.D. Anderson Cancer Center Chronic lymphocytic leukemia (CLL), Acute lymphoblastic leukaemia (ALL), Non-Hodgkin's lymphoma (NHL) Details
Anti-CD22/CD19 monoclonal antibody-toxin conjugate Phase Ⅰ University of Texas Southwestern Medical Center, Galileo Research B-cell lymphoma, Acute lymphoblastic leukaemia (ALL) Details
Dual specificity CD19 and CD20 or CD22 CAR-T cell (Chinese PLA General Hospital) Phase Ⅱ General Hospital of the People's Liberation Army B-cell lymphoma, Leukemia Details
4SCAR-T cell therapy (Shenzhen Geno-Immune Medical Institute) 4SCAR-T Phase Ⅱ Shenzhen Geno-Immune Medical Institute B-cell malignancies Details
Epratuzumab I-131 Phase Ⅱ Immunomedics, Repligen Non-Hodgkin's lymphoma (NHL) Details
UCART-22 UCART-22 Phase Ⅰ Cellectis Acute lymphoblastic leukaemia (ALL) Details
Pinatuzumab vedotin DCDT-2980S; FCU-2703; RG-7593; RO-5541072; RO-5541072-000; ACD22-VCMMAE Phase Ⅱ Genentech Diffuse large B cell lymphoma, Chronic lymphocytic leukemia (CLL), Non-Hodgkin's lymphoma (NHL) Details
CD22-targeted CAR-T cell therapy (PersonGen Biomedicine) Phase Ⅰ PersonGen Biomedicine B-cell lymphoma Details
Anti-CD19 and anti-CD22 CAR T cell therapy (Seattle Children's Hospital) Phase Ⅰ Seattle Children's Hospital Acute lymphoblastic leukaemia (ALL) Details
Anti-CD22-CAR T cell therapy (Kecellitics Biotech) Phase Ⅱ Kecellitics Biotech Company Ltd Leukemia, Lymphoma Details
Anti-CD22 CAR T cell therapy (Shanghai GeneChem) Phase Ⅰ Shanghai GeneChem Chronic lymphocytic leukemia (CLL), Acute lymphoblastic leukaemia (ALL), Non-Hodgkin B-cell lymphomas Details
Bectumomab Phase Ⅲ Immunomedics Non-Hodgkin's lymphoma (NHL) Details
CART22-cells CART22-cells Phase Ⅰ University of Pennsylvania, Novartis B-cell lymphoma, Leukemia Details
Anti-CD19/CD22 CAR-T cell therapy (Jiao Tong University) Phase Ⅰ Shanghai Jiaotong University Acute lymphoblastic leukaemia (ALL) Details
Chimeric antigen receptor T cell therapeutics (Shanghai Unicar-Therapy Bio-medicine) Phase Ⅱ Shanghai Unicar-Therapy Bio-medicine Technology Non-Hodgkin's lymphoma (NHL) Details
Anti-CD22 CAR T cell therapy (Wuhan Bio-Raid) Phase Ⅰ Wuhan Bio-Raid Biotechnology B-cell lymphoma, Multiple myeloma (MM) Details
Dual anti-CD19/CD22 CAR‐T cell therapy (B-cell malignancies, Stanford University) Phase Ⅰ Stanford University B-cell lymphoma Details
Epratuzumab Y-90 90Y-DOTA-hLL2; 90Y-hLL2; hCD22-Y-90; IMMU-102 Phase Ⅱ Immunomedics, Nantes University Hospital Diffuse large B cell lymphoma, Acute lymphoblastic leukaemia (ALL), Non-Hodgkin's lymphoma (NHL) Details
Anti-CD19/CD22 bispecific CAR-T cell therapy (The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine) Phase Ⅰ The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine Acute lymphoblastic leukaemia (ALL) Details
Anti-CD22 monoclonal antibody-toxin conjugate (Galileo Research/the University of Texas) IMTOX-22 Phase Ⅰ University of Texas Southwestern Medical Center, Royal Free and University College Medical School, Cancer Research Technology, National Institutes of Health, Galileo Research, Abiogen Pharma Non-Hodgkin B-cell lymphomas Details
CAT-3888 CAT-3888; BL-22 Phase Ⅱ Cambridge Antibody Technology, National Institutes of Health, MedImmune Lymphoblastic leukaemia, Chronic lymphocytic leukemia (CLL), Hairy cell leukemia, Non-Hodgkin's lymphoma (NHL) Details
RFB4-SMPT-dgA RFB4-SMPT-dgA; IgG-RFB4-SMPT-dgA; NSC639179 Phase Ⅰ National Cancer Institute, University of Texas Southwestern Medical Center B-cell lymphoma Details
Anti-CD19/22-CAR vector-transduced T cell therapy (Chinese PLA General Hospital) Phase Ⅱ General Hospital of the People's Liberation Army Leukemia, Lymphoma Details
TRPH-222 TRPH-222; CAT-02-106; CD22-4AP Phase Ⅰ Catalent, Triphase Accelerator B-cell lymphoma Details
Anti-CD22 CAR-T cell therapy (iCarTAB BioMed) Phase Ⅱ iCarTAB Biomed B-cell lymphoma Details
Anti CD22 chimeric antigen receptor T cell therapy (Shanghai Yake Biotechnology) Phase Ⅱ Yake Biotechnology, The First Affiliated Hospital of Zhejiang University School of Medicine, Beijing Boren Hospital Acute lymphoblastic leukaemia (ALL) Details

This web search service is supported by Google Inc.

totop